Different fusion genes such as RBM15::MRTFA (20%), CBFA2T3::GLIS2 (16%), NUP98 (10%), KMT2A (7%), TEC::MLLT10 (2%), MECOM (1%) and FUS::ERG (1%) were identified, disappointingly, AMKL patients with CBFA2T3::GLIS2 or KMT2A rearrangement and NUP98 fusion gene have a poorer prognosis than other patients, while those with RBM15::MRTFA have a better prognosis, which will assist in risk stratification and treatment selection for AMKL patients. The gene discussed is KMT2A; the disease is acute megakaryoblastic leukemia.